Inventor · disambiguated record
Peter S. Linsley
Also filed as: LINSLEY PETER · LINSLEY PETER S
83 granted patents·29 pending applications·6,670 citations·filing 1984–2024
99Inventor score
Files withBRISTOL MYERS SQUIBB CO52ONCOGEN10SAREPTA THERAPEUTICS INC5ROSETTA INPHARMATICS LLC4LINSLEY PETER3
Top patents by PatentIndex Score
112 records- 0199US7595387B2Modified polynucleotides for reducing off-target effects in RNA interferenceDHARMACON INC·Filed 2004·Granted Sep 29, 2009·173 cites·10 claims
- 0299US5977318ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 2, 1999·438 cites·4 claims
- 0398US6623940B1Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 23, 2003·133 cites·17 claims
- 0498US6132992AExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Oct 17, 2000·387 cites·54 claims
- 0598US5844095ACTLA4 Ig fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 1, 1998·417 cites·2 claims
- 0698US5637481AExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jun 10, 1997·331 cites·22 claims
- 0798US5434131AChimeric CTLA4 receptor and methods for its useBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jul 18, 1995·374 cites·8 claims
- 0897US7094874B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Aug 22, 2006·86 cites·42 claims
- 0997US7013221B1Iterative probe design and detailed expression profiling with flexible in-situ synthesis arraysROSETTA INPHARMATICS LLC·Filed 2000·Granted Mar 14, 2006·129 cites·90 claims
- 1097US5968510ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Oct 19, 1999·157 cites·1 claims
- 1197US5916560AMethods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewithBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Jun 29, 1999·175 cites·24 claims
- 1297US5885796ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 23, 1999·199 cites·12 claims
- 1397US5580756AB7Ig fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Dec 3, 1996·238 cites·3 claims
- 1497US5521288ACD28IG fusion proteinBRISTOL MYERS SQUIBB CO·Filed 1994·Granted May 28, 1996·233 cites·2 claims
- 1596US7514209B2Diagnosis and prognosis of breast cancer patientsROSETTA INPHARMATICS LLC·Filed 2002·Granted Apr 7, 2009·139 cites·44 claims
- 1696US7311910B2Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactionsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Dec 25, 2007·40 cites·9 claims
- 1796US5851795ASoluble CTLA4 molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 22, 1998·182 cites·21 claims
- 1896US5773253AMYPPPY variants of CTL A4 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Jun 30, 1998·172 cites·17 claims
- 1996US5770197AMethods for regulating the immune response using B7 binding molecules and IL4-binding moleculesBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Jun 23, 1998·200 cites·11 claims
- 2095US7304033B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 4, 2007·90 cites·32 claims
- 2195US7171311B2Methods of assigning treatment to breast cancer patientsNETHERLANDS CANCER INST·Filed 2003·Granted Jan 30, 2007·289 cites·33 claims
- 2295US6090914ACTLA4/CD28Ig hybrid fusion proteins and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1994·Granted Jul 18, 2000·149 cites·7 claims
- 2395US5709859AMixed specificity fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 1991·Granted Jan 20, 1998·143 cites·22 claims
- 2494US7105166B1Soluble CTLA4 mutant molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 12, 2006·33 cites·12 claims
- 2594US6830937B1Method for generating and identifying antibodies directed against a B7BRISTOL MYERS SQUIBB CO·Filed 2000·Granted Dec 14, 2004·39 cites·5 claims
- 2694US6482919B2Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cellBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 19, 2002·68 cites·6 claims
- 2794US5849876AHybridomas producing monoclonal antibodies to new mucin epitopesSANOFI SA·Filed 1994·Granted Dec 15, 1998·142 cites·3 claims
- 2893US8014957B2Genes associated with progression and response in chronic myeloid leukemia and uses thereofHUTCHINSON FRED CANCER RES·Filed 2006·Granted Sep 6, 2011·46 cites·16 claims
- 2993US7700556B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Apr 20, 2010·14 cites·8 claims
- 3093US6887471B1Method to inhibit T cell interactions with soluble B7BRISTOL MYERS SQUIBB CO·Filed 1999·Granted May 3, 2005·66 cites·5 claims
- 3193US6271002B1RNA amplification methodROSETTA INPHARMATICS INC·Filed 1999·Granted Aug 7, 2001·203 cites·102 claims
- 3293US5885579ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 23, 1999·122 cites·11 claims
- 3392US7455835B2Methods for treating immune system diseases using a soluble CTLA4 moleculeBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Nov 25, 2008·57 cites·31 claims
- 3491US7572772B2Soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Aug 11, 2009·10 cites·6 claims
- 3590US7829534B2Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Nov 9, 2010·16 cites·14 claims
- 3690US7439230B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 21, 2008·22 cites·16 claims
- 3790US6641809B1Method of regulating cellular processes mediated by B7 and CD28BRISTOL MYERS SQUIBB CO·Filed 1994·Granted Nov 4, 2003·84 cites·16 claims
- 3889US9758565B2Methods of treatment using CTLA4 mutant moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 12, 2017·6 cites·14 claims
- 3988US8846631B2MicroRNA compositions and methodsMARCUSSON ERIC G·Filed 2011·Granted Sep 30, 2014·9 cites·15 claims
- 4088US4935495AMonoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomasONCOGEN·Filed 1984·Granted Jun 19, 1990·45 cites·16 claims
- 4187US12006366B2Methods and compositions for preventing type 1 diabetesPROVENTION BIO INC·Filed 2021·Granted Jun 11, 2024·2 cites·23 claims
- 4287US5993800AMethods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligandBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 30, 1999·93 cites·10 claims
- 4387US4906562AMonocolonal antibodies and antigen for human non-small cell lung carcinomasONCOGEN·Filed 1985·Granted Mar 6, 1990·61 cites·28 claims
- 4486US5795572AMonoclonal antibodies and FV specific for CD2 antigenBRISTOL MYERS SQUIBB CO·Filed 1993·Granted Aug 18, 1998·68 cites·24 claims
- 4586US5091177AMonoclonal antibodies for treatment of human non-small cell lung carcinomasONCOGEN·Filed 1990·Granted Feb 25, 1992·59 cites·33 claims
- 4685US9944926B2Induced exon inclusion in spinal muscle atrophySAREPTA THERAPEUTICS INC·Filed 2012·Granted Apr 17, 2018·10 cites·18 claims
- 4784US8785398B2Methods of treatment using CTLA4 mutant moleculesPEACH ROBERT JAMES·Filed 2011·Granted Jul 22, 2014·6 cites·11 claims
- 4884US7863001B2Diagnosis and prognosis of breast cancer patientsNETHERLANDS CANCER INST·Filed 2008·Granted Jan 4, 2011·7 cites·9 claims
- 4984US6384198B1Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigenBRISTOL MYERS SQUIBB CO·Filed 1995·Granted May 7, 2002·54 cites·4 claims
- 5084US4737579AMonoclonal antibodies for human non-small cell lung carinomasONCOGEN·Filed 1986·Granted Apr 12, 1988·35 cites·24 claims
Showing the top 50 of 112 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Peter S. Linsley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →